IR-News

AUSSENDER



Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
E-Mail: ir@biofrontera.com
pta20211029002
Public disclosure of inside information according to article 17 MAR

Biofrontera AG: Initial public offering price of Biofrontera Inc. IPO


Leverkusen, Germany (pta002/29.10.2021/03:40) - Leverkusen, Germany, October 29, 2021- On July 6, 2021, Biofrontera AG announced that its US-subsidiary Biofrontera Inc. intends to raise capital by means of an initial public offering and a stock exchange listing in the United States ("IPO"). On October 27, 2021, Biofrontera Inc. announced that up to 3,565,000 units ("Units") consisting of one new Biofrontera Inc. share and one warrant entitling the holder to one additional new Biofrontera Inc. share shall be offered in the IPO. The public offering price of a Unit is allocated between the share and the warrant. Each warrant has an exercise price equal to the initial public offering price and expires five years from the date of issuance.

Biofrontera Inc. has now set that 3,600,000 Units will be offered at a public offering price of USD 5.00 per Unit, of which USD 4.99 per Unit is allocated to one share and USD 0.01 per Unit is allocated to one warrant.

In addition, Biofrontera has granted the underwriters a 30-day option to purchase additional 540,000 shares of its common stock and/or warrants to purchase up to an additional 540,000 of its common stock, at the initial public offering price, less the underwriting discounts and commissions.

Biofrontera Inc. expects gross proceeds from the IPO (excluding the over-allotment), before deduction of underwriting discounts and commissions and offering expenses, to be USD 18,000,000.

This offering is being made only by means of a prospectus which has been filed with the U.S. Securities and Exchange Commission as part of an effective registration statement.

This public disclosure of inside information according to article 17 MAR shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(end)
emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE0006046113 (share)
other stock exchanges: Nasdaq
|
|
98.653 Abonnenten
|
199.927 Meldungen
|
82.569 Pressefotos

BUSINESS

25.05.2022 - 13:20 | SRH AlsterResearch AG
25.05.2022 - 13:00 | Karriereforum Salzburger Nachrichten Verlagsgesellschaft m.b.H. & Co KG
25.05.2022 - 12:45 | movea marketing GmbH & Co KG
25.05.2022 - 11:30 | pressetext.redaktion
25.05.2022 - 11:25 | SRH AlsterResearch AG
Top